Author: admin

Credit: onurdongel / Getty Images / E+ Research led by Mount Sinai Health System shows artificial intelligence (AI)-based large language models (LLMs) remain susceptible to medical misinformation, particularly if it is phrased in language that implies it comes from a medical expert. “AI has the potential to be a real help for clinicians and patients, offering faster insights and support,” says co-lead investigator Girish Nadkarni, MD, a professor at the Icahn School of Medicine at Mount Sinai, and chief AI officer of the Mount Sinai Health System, in a press statement. “But it needs built-in safeguards that check medical claims…

Credit: PM Images / Getty Images / Stone Influenza infection is estimated to cause one billion annual infections globally. While most infections result in symptoms that are mild and self-resolving, some infections may trigger consequences in the heart including cardiomyocyte death leading to desynchronized contraction. The connection between influenza and cardiovascular conditions has been well documented, however, the mechanisms connecting the respiratory infection to heart function are unclear. “We have known for years that the frequency of heart attacks increases during flu season, yet outside of clinical intuition, scant evidence exists of the underlying mechanisms of that phenomenon,” said senior…

Credit: Mark Kostich/GettyImages For decades, clinicians managing biochemical recurrence after radical prostatectomy have faced a familiar dilemma: prostate-specific antigen (PSA) rises, conventional imaging remains negative, and salvage radiotherapy (sRT) proceeds largely empirically. That paradigm is now being challenged by prostate-specific membrane antigen (PSMA) PET/CT, which can reveal recurrent disease at PSA levels once considered “below the radar.” A new study published in JNCCN—Journal of the National Comprehensive Cancer Network provides some of the most mature outcome data yet on what PSMA-guided decision-making actually delivers in practice. Using real-world data from UCLA, investigators report five-year outcomes in men who underwent PSMA PET/CT–guided…

Credit: Itsanan Sampuntarat / iStock / Getty Images Opentrons is using Nvidia’s Isaac and Cosmos artificial intelligence (AI) platforms to generate training data needed to develop and deploy physical AI-enabled laboratory robotics. The company’s goal is to help current and future customers of its systems use physical AI, to improve everyday laboratory workflows. Opentrons made the announcement last week ahead of this year’s international meeting of the Society for Laboratory Automation and Screening held in Boston from February 7–11. To date, Opentrons has installed more than 10,000 robotic systems in various research universities and biopharmaceutical companies and ships about 800…

Credit: Bangkokerz/Getty Images Research testing the real world impact of the newly FDA approved Apple Watch hypertension alert shows receiving an alert is a useful push for people to get further screening, but the overall accuracy could be better. A previously published validation study of the Apple alert suggested 41.2% of people with undiagnosed hypertension would receive an alert for potentially having the condition and 58.8% would not.  In those without hypertension, the study predicted 92.3% would not receive an alert and 7.7% would receive an inappropriate alert. “With more than 200 million Apple Watch users worldwide, the hypertension notification…

Antibiotic resistance has steadily accelerated in recent years to become a global health crisis with estimates of more than 10 million worldwide deaths per year by 2050. Antibiotic-resistant bacteria are known to flourish in hospital settings, sewage treatment areas, animal husbandry locations and fish farms.   In a new study published in npj Antimicrobials and Resistance titled, “A conjugal gene drive-like system efficiently suppresses antibiotic resistance in a bacterial population,” researchers from University of California, San Diego (UCSD) have developed a novel CRISPR-based technology for removing antibiotic resistant elements from populations of bacteria. The Pro-Active Genetics (Pro-AG) tool, named pPro-MobV, is a second-generation…

Takeda Pharmaceutical will apply Iambic Therapeutics’ artificial intelligence (AI)-based technologies and wet lab capabilities to design and develop small molecule drugs starting with two of Takeda’s therapeutic areas through a multi-year tech and discovery collaboration that could generate more than $1.7 billion for the San Diego biotech, the companies said. Takeda has agreed to use Iambic’s AI drug discovery models toward advancing a set of high-priority small molecule programs in the pharma’s therapeutic areas of oncology and gastrointestinal and inflammation. In addition to oncology and gastrointestinal and inflammation, Takeda’s areas of therapeutic focus include neuroscience, plasma-derived therapies, rare diseases, and…

Chronic constipation is common, but available dietary advice is vague Chronic constipation, defined as fewer than three bowel movements a week, hard stool or difficulty passing stool in the absence of an underlying pathology, is a long-term condition that impacts quality of life and places an economic burden on both patients and healthcare systems. Chronic constipation is due to a wide range of causes, with emerging studies suggesting gut transit may impact the gut microbiota, which opens new ways of managing constipation. For years, dietary advice for constipation has been vague, with people told to increase fiber intake and drink…

Bristol Myers Squibb (NYSE: BMY; BMS) delivered some good news to investors in reporting fourth-quarter and full-year 2025 results on Thursday. The pharma giant beat analyst consensus forecasts by reporting higher than expected numbers for total revenue and its “growth” portfolio of drugs on which BMS is counting on for long-term growth to offset revenue declines from its aging blockbusters set to lose patent exclusivity over the next two years. As a result, BMS shares climbed 3% on Thursday from $57.62 to $59.52 despite a day of declines for key stock market indexes, after an initial 5% surge to $60.56…

Phase 1 dosing milestone for MEN2501 signals growing confidence in generative AI drug discovery and its healthspan implications. There is a quiet moment in every drug’s life when it stops being an idea and starts becoming a responsibility. For MEN2501, that moment arrived when the first patient received a dose. AI-powered clinical-stage biotech Insilico Medicine has now collected a $5 million milestone payment from the Menarini Group after achieving first-in-patient dosing in a Phase 1 clinical trial of MEN2501, a drug candidate designed using Insilico’s generative AI platform [1]. The payment follows an earlier $3 million milestone triggered by regulatory…